Related Experiment Videos
Comparative renal pathophysiology relevant to IDDM and NIDDM patients
C E Mogensen1, A Schmitz, C K Christensen
1Medical Department M, Second University Clinic of Internal Medicine, Kommunehospitalet, Aarhus, Denmark.
Diabetes/Metabolism Reviews
|August 1, 1988
Summary
Hyperfiltration, common in insulin-dependent diabetes, may contribute to diabetic nephropathy. However, some patients with poor metabolic control but no hyperfiltration appear protected, suggesting complex renal protection mechanisms in diabetes.
Area of Science:
- Nephrology
- Endocrinology
- Diabetology
Background:
- Hyperfiltration is a hallmark of insulin-dependent diabetes (IDDM), with a weak correlation to glycemic control.
- Long-term hyperfiltration may contribute to diabetic nephropathy, but its independent role is debated.
- Diabetic nephropathy development requires metabolic derangements alongside glomerular wall biochemistry changes.
Purpose of the Study:
- To explore the role of hyperfiltration in diabetic nephropathy development.
- To investigate protective mechanisms in diabetic patients without nephropathy.
- To evaluate potential therapeutic interventions for preventing or delaying diabetic nephropathy.
Main Methods:
- Review of existing literature on hyperfiltration and diabetic nephropathy.
- Analysis of the relationship between metabolic control, hyperfiltration, and nephropathy.
- Discussion of non-glycemic and antihypertensive interventions.
Main Results:
- Long-term hyperfiltration without diabetes does not cause nephropathy.
- IDDM patients with poor metabolic control but no hyperfiltration may be protected from nephropathy.
- Diabetic glomerulopathy in non-insulin-dependent diabetes (NIDDM) occurs without significant hyperfiltration.
- Antihypertensive treatment, including ACE inhibitors, slows GFR decline and reduces proteinuria in established and incipient diabetic nephropathy.
Conclusions:
- Hyperfiltration is a risk factor, but not the sole cause, of diabetic nephropathy.
- Metabolic derangements are essential for diabetic nephropathy development.
- Nonglycemic interventions (e.g., low-protein diet, somatostatin analogues, aldose-reductase inhibitors) and antihypertensive therapy show promise in managing or preventing diabetic nephropathy.